Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benralizumab in Severe Eosinophilic Asthma
NCT03953300Phase 4Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Oct 2019
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 4, randomised, double-blind trial in eosinophilic asthma (EA) comparing Benralizumab with Placebo (2 arms). Primary endpoints: Change in eosinophil numbers in submucosa at 48 weeks and Change in airway wall area percentage at 48 weeks. Started Oct 2019; status: active, not recruiting.
02
Drugs
benralizumab
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on NCT03953300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03953300.